Loading asset research
Braveheart Bio Inc. Common Stock
BRVENasdaq · USD · StocksQuote as of · Exchange session not verified$26.70
-2.02%
Today
BRVE
Loading 1D prices…
Market cap
$2.4B
Volume
283.6K
52w high
$32.0052w low
$24.31Company profile
Braveheart Bio Inc. Common Stock
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
San Francisco, CA, United States
Employees
49
Fiscal year end
1231
CIK
2131524
Session & valuation
Open$28.12
Previous close$27.25
Day high$28.74
Day low$26.54
30-day avg. volume472.8K
Outstanding shares90M
Diluted EPS-$5.32
Latest annual period
P/E (trailing)-5.02
P/E (forward)-13.39
Price / book-2.32
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| VRDNViridian Therapeutics Inc. Common Stock | $2.4B | $70.8M | -483.56% | -$3.32 | -4.76% | Buy |
| NKTRNektar Therapeutics Common Stock | $2.4B | $55.2M | -296.93% | -$9.73 | -1.25% | Buy |
| HRMYHarmony Biosciences Holdings Inc. Common Stock | $2.4B | $868.5M | +18.27% | $2.71 | +1.02% | Hold |
| MRVIMaravai LifeSciences Holdings Inc. Class A Common Stock | $2.4B | $185.7M | -70.42% | -$0.90 | -3.12% | Buy |
| SUPNSupernus Pharmaceuticals Inc. Common Stock | $2.4B | $719M | -5.37% | -$0.68 | -0.10% | Buy |